IMA Key Statistics, Chart & Performance
The current stock price of IMA is 7.325 USD. In the past month the price increased by 3.02%.
IMA Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to IMA.
IMA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMA. IMA has a great financial health rating, but its profitability evaluates not so good.
IMA Financial Highlights
Over the last trailing twelve months IMA reported a non-GAAP Earnings per Share(EPS) of -8.07. The EPS increased by 47.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.6% | ||
| ROE | -35.21% | ||
| Debt/Equity | 0 |
IMA Forecast & Estimates
7 analysts have analysed IMA and the average price target is 16.32 USD. This implies a price increase of 122.8% is expected in the next year compared to the current price of 7.325.
IMA Ownership
About IMA
Company Profile
ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. The company is headquartered in San Diego, California and currently employs 15 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The firm develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The firm is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
Company Info
IMAGENEBIO INC
12526 High Bluff Drive
San Diego CALIFORNIA US
Employees: 15
Phone: 18573438292
IMAGENEBIO INC / IMA FAQ
Can you describe the business of IMAGENEBIO INC?
ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. The company is headquartered in San Diego, California and currently employs 15 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing disease-modifying treatments for immunological/autoimmune and inflammatory (I&I) diseases. The firm develops differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The Company’s lead asset is IMG-007, a novel non-depleting anti-OX40 mAb bioengineered with Fc N297A mutations to abolish antibody-dependent cellular cytotoxicity (ADCC). IMG-007 is designed to specifically bind to OX40 on activated T cells and block the interaction between OX40 and OX40L without killing the T cells. The firm is conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.
Can you provide the latest stock price for IMAGENEBIO INC?
The current stock price of IMA is 7.325 USD. The price decreased by -0.88% in the last trading session.
Does IMAGENEBIO INC pay dividends?
IMA does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMA stock?
IMA has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for IMA stock?
IMAGENEBIO INC (IMA) currently has 15 employees.
What is IMAGENEBIO INC worth?
IMAGENEBIO INC (IMA) has a market capitalization of 81.89M USD. This makes IMA a Micro Cap stock.
Can you provide the ownership details for IMA stock?
You can find the ownership structure of IMAGENEBIO INC (IMA) on the Ownership tab.